Business Description
Ascletis Pharma Inc
ISIN : KYG0520K1094
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 234.91 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 5.24 | |||||
Beneish M-Score | -3.94 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.2 | |||||
3-Year EBITDA Growth Rate | 14.8 | |||||
3-Year EPS without NRI Growth Rate | -7 | |||||
3-Year FCF Growth Rate | -5.6 | |||||
3-Year Book Growth Rate | -8.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | -10.75 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 93.36 | |||||
9-Day RSI | 83.69 | |||||
14-Day RSI | 75.67 | |||||
6-1 Month Momentum % | -27.15 | |||||
12-1 Month Momentum % | -53.39 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 24.38 | |||||
Quick Ratio | 24.31 | |||||
Cash Ratio | 23.97 | |||||
Days Inventory | 213.5 | |||||
Days Sales Outstanding | 427.34 | |||||
Days Payable | 43.16 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.8 | |||||
Shareholder Yield % | 8.45 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -125.17 | |||||
Operating Margin % | -3797.94 | |||||
Net Margin % | -2541.38 | |||||
FCF Margin % | -2858.33 | |||||
ROE % | -10.9 | |||||
ROA % | -10.41 | |||||
ROIC % | -230.99 | |||||
3-Year ROIIC % | 111.31 | |||||
ROC (Joel Greenblatt) % | -386.72 | |||||
ROCE % | -10.85 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 137 | |||||
PB Ratio | 0.59 | |||||
Price-to-Tangible-Book | 0.6 | |||||
EV-to-EBIT | 3.29 | |||||
EV-to-EBITDA | 3.29 | |||||
EV-to-Revenue | -83.56 | |||||
EV-to-FCF | 2.95 | |||||
Price-to-Projected-FCF | 5 | |||||
Price-to-Net-Current-Asset-Value | 0.63 | |||||
Price-to-Net-Cash | 0.65 | |||||
Earnings Yield (Greenblatt) % | 30.4 | |||||
FCF Yield % | -22.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ascletis Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 1.296 | ||
EPS (TTM) (€) | -0.031 | ||
Beta | 0.54 | ||
Volatility % | 73.13 | ||
14-Day RSI | 75.67 | ||
14-Day ATR (€) | 0.006009 | ||
20-Day SMA (€) | 0.116625 | ||
12-1 Month Momentum % | -53.39 | ||
52-Week Range (€) | 0.084 - 0.238 | ||
Shares Outstanding (Mil) | 993.75 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ascletis Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ascletis Pharma Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ascletis Pharma Inc Frequently Asked Questions
What is Ascletis Pharma Inc(FRA:2VJ)'s stock price today?
When is next earnings date of Ascletis Pharma Inc(FRA:2VJ)?
Does Ascletis Pharma Inc(FRA:2VJ) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |